DRMADermata Therapeutics, Inc.vs its industry peers
A metric-by-metric comparison of Dermata Therapeutics, Inc. against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DRMAThis | $3M#7 | — | 0.9x#4 | — | — | 38.5%#3 | — | -216.7%#3 | — | — | -78.0%#1 | — |
| TRAW | $4M#1 | — | 0.4x#3 | 1.6x#1 | 1134.5%#1 | 105.5%#1 | -640.7%#1 | 79.2%#1 | — | — | -88.5%#2 | — |
| CVKD | $4M#2 | — | 0.9x#5 | — | — | -24.3%#6 | — | -323.5%#6 | -585.1%#3 | — | — | — |
| GRI | $3M#3 | — | 0.3x#1 | — | -100.0%#4 | -45.7%#7 | — | -116.3%#2 | — | — | — | — |
| KALA | $3M#4 | 0.0x#1 | 0.4x#2 | — | — | 29.9%#4 | — | -298.3%#5 | -69.9%#1 | — | — | — |
| ERNA | $3M#5 | 0.0x#2 | 1.0x#6 | 5.6x#3 | 755.9%#2 | 68.4%#2 | -1601.2%#3 | -440.1%#7 | -1016.2%#4 | — | — | — |
| SXTP | $3M#6 | — | 1.2x#7 | 3.2x#2 | 65.5%#3 | 7.3%#5 | -771.6%#2 | -281.7%#4 | -163.8%#2 | 6#1 | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. This table timed out mid-build, so it covers part of the group; ranks are within the rows shown and it fills in shortly. Table built 2026-11-03.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice